|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2002-6-19
|
|
pubmed:abstractText |
Currently, there is tremendous uncertainty regarding how giant congenital melanocytic nevi (GCMN) should be treated. Our approach to patients with GCMN is based on 2 main considerations: (1) obtain an acceptable cosmetic result to decrease the psychosocial inconvenience to the patient, and (2) attempt to minimize the risk of malignancy. For the past 10 years we have treated GCMN by curettage in the neonatal period. We report our experience and results.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0003-987X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
138
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
943-7
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:12071822-Antigens, Neoplasm,
pubmed-meshheading:12071822-Child, Preschool,
pubmed-meshheading:12071822-Curettage,
pubmed-meshheading:12071822-Female,
pubmed-meshheading:12071822-Follow-Up Studies,
pubmed-meshheading:12071822-Humans,
pubmed-meshheading:12071822-Infant,
pubmed-meshheading:12071822-Infant, Newborn,
pubmed-meshheading:12071822-Male,
pubmed-meshheading:12071822-Melanoma-Specific Antigens,
pubmed-meshheading:12071822-Neoplasm Proteins,
pubmed-meshheading:12071822-Nevus, Pigmented,
pubmed-meshheading:12071822-Skin,
pubmed-meshheading:12071822-Skin Neoplasms,
pubmed-meshheading:12071822-Treatment Outcome,
pubmed-meshheading:12071822-Wound Healing
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Curettage of giant congenital melanocytic nevi in neonates: a decade later.
|
|
pubmed:affiliation |
Department of Dermatology, Academic Hospital Vrije Universiteit Brussel, Brussels, Belgium. linda.deraeve@az.vub.ac.be
|
|
pubmed:publicationType |
Journal Article
|
